260 related articles for article (PubMed ID: 38360860)
21. Proteomic research in sarcomas - current status and future opportunities.
Burns J; Wilding CP; L Jones R; H Huang P
Semin Cancer Biol; 2020 Apr; 61():56-70. PubMed ID: 31722230
[TBL] [Abstract][Full Text] [Related]
22. Emerging predictive biomarkers in the management of bone and soft tissue sarcomas.
Haddox CL; Riedel RF
Expert Rev Anticancer Ther; 2023 May; 23(5):495-502. PubMed ID: 37017995
[TBL] [Abstract][Full Text] [Related]
23. Extrarenal rhabdoid tumors of soft tissue: clinicopathological and molecular genetic review and distinction from other soft-tissue sarcomas with rhabdoid features.
Oda Y; Tsuneyoshi M
Pathol Int; 2006 Jun; 56(6):287-95. PubMed ID: 16704491
[TBL] [Abstract][Full Text] [Related]
24. Loss of p16(INK4a) is associated with reduced patient survival in soft tissue tumours, and indicates a senescence barrier.
Knösel T; Altendorf-Hofmann A; Lindner L; Issels R; Hermeking H; Schuebbe G; Gibis S; Siemens H; Kampmann E; Kirchner T
J Clin Pathol; 2014 Jul; 67(7):592-8. PubMed ID: 24747207
[TBL] [Abstract][Full Text] [Related]
25. PD-1, PD-L1, IDO, CD70 and microsatellite instability as potential targets to prevent immune evasion in sarcomas.
Siozopoulou V; Smits E; Zwaenepoel K; Liu J; Pouliakis A; Pauwels PA; Marcq E
Immunotherapy; 2023 Oct; 15(15):1257-1273. PubMed ID: 37661910
[TBL] [Abstract][Full Text] [Related]
26. [Pleomorphic high-grade soft tissue sarcomas: is the subclassification up to date?].
Mechtersheimer G; Renner M; Penzel R; Schirmacher P
Pathologe; 2011 Feb; 32(1):47-56. PubMed ID: 21234572
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological and prognostic significance of chemokine receptor CXCR4 in patients with bone and soft tissue sarcoma: a meta-analysis.
Li YJ; Dai YL; Zhang WB; Li SJ; Tu CQ
Clin Exp Med; 2017 Feb; 17(1):59-69. PubMed ID: 26678086
[TBL] [Abstract][Full Text] [Related]
28. Emerging Trends in Immunotherapy for Adult Sarcomas.
Husain M; Chen L; Liebner D; Beane J; Rubinstein M; Pollock R; Verschraegen C; Tinoco G
Oncologist; 2023 May; 28(5):e233-e241. PubMed ID: 36905579
[TBL] [Abstract][Full Text] [Related]
29. The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma.
Ryan CW; Desai J
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714556
[TBL] [Abstract][Full Text] [Related]
30. Identification of Prognostic lncRNA Related to the Immune Microenvironment of Soft Tissue Sarcoma.
Dai WY; Wang B; Li JY; Luo ZP
Biomed Res Int; 2022; 2022():9471558. PubMed ID: 35155682
[TBL] [Abstract][Full Text] [Related]
31. Prognostic attributes of immune signatures in soft tissue sarcomas show differential dependencies on tumor mutational burden.
Raj SKS; Routh ED; Chou JW; Votanopoulos KI; Triozzi PL; Miller LD
Cancer; 2022 Sep; 128(17):3254-3264. PubMed ID: 35767280
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy in Sarcoma: Where Do Things Stand?
Moreno Tellez C; Leyfman Y; D'Angelo SP; Wilky BA; Dufresne A
Surg Oncol Clin N Am; 2022 Jul; 31(3):381-397. PubMed ID: 35715140
[TBL] [Abstract][Full Text] [Related]
33. Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma.
Dufresne A; Lesluyes T; Ménétrier-Caux C; Brahmi M; Darbo E; Toulmonde M; Italiano A; Mir O; Le Cesne A; Le Guellec S; Valentin T; Chevreau C; Bonvalot S; Robin YM; Coindre JM; Caux C; Blay JY; Chibon F
Oncoimmunology; 2020 Jul; 9(1):1792036. PubMed ID: 32923153
[TBL] [Abstract][Full Text] [Related]
34. Integrated molecular characterization of adult soft tissue sarcoma for therapeutic targets.
Kim J; Kim JH; Kang HG; Park SY; Yu JY; Lee EY; Oh SE; Kim YH; Yun T; Park C; Cho SY; You HJ
BMC Med Genet; 2018 Dec; 19(Suppl 1):216. PubMed ID: 30598078
[TBL] [Abstract][Full Text] [Related]
35. Quantitative proteomic profiling of pleomorphic human sarcoma identifies CLIC1 as a dominant pro-oncogenic receptor expressed in diverse sarcoma types.
Murray E; Hernychová L; Scigelova M; Ho J; Nekulova M; O'Neill JR; Nenutil R; Vesely K; Dundas SR; Dhaliwal C; Henderson H; Hayward RL; Salter DM; Vojtěšek B; Hupp TR
J Proteome Res; 2014 May; 13(5):2543-59. PubMed ID: 24661138
[TBL] [Abstract][Full Text] [Related]
36. Inhibitory checkpoint molecule mRNA expression in canine soft tissue sarcoma.
Stevenson VB; Gudenschwager-Basso EK; Klahn S; LeRoith T; Huckle WR
Vet Comp Oncol; 2023 Dec; 21(4):709-716. PubMed ID: 37680007
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A systematic review and meta-analysis.
Zheng C; You W; Wan P; Jiang X; Chen J; Zheng Y; Li W; Tan J; Zhang S
Medicine (Baltimore); 2018 Jun; 97(25):e11004. PubMed ID: 29923984
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathologic assessment of postradiation sarcomas: KIT as a potential treatment target.
Komdeur R; Hoekstra HJ; Molenaar WM; Van Den Berg E; Zwart N; Pras E; Plaza-Menacho I; Hofstra RM; Van Der Graaf WT
Clin Cancer Res; 2003 Aug; 9(8):2926-32. PubMed ID: 12912938
[TBL] [Abstract][Full Text] [Related]
39. [Soft tissue sarcoma in the head and neck--analysis of 87 patients].
Ou SM
Zhonghua Zhong Liu Za Zhi; 1988 Jul; 10(4):289-92. PubMed ID: 3248487
[TBL] [Abstract][Full Text] [Related]
40. DNA hypermethylation status of multiple genes in soft tissue sarcomas.
Kawaguchi K; Oda Y; Saito T; Yamamoto H; Takahira T; Kobayashi C; Tamiya S; Tateishi N; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2006 Jan; 19(1):106-14. PubMed ID: 16258501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
